BG45

SKU: orb1305773

Description

BG45 is a selective HDAC I inhibitor, exhibiting potent activity against HDAC3 (IC50 = 289 nM) with weaker effects on HDAC1, HDAC2, and HDAC6. This small molecule is a valuable research tool for studying epigenetic mechanisms in cancer biology and neuroscience, applicable in both cellular and biochemical assays.

Research Area

Epigenetics & Chromatin, Neuroscience

Key Properties

• CAS Number: 926259-99-6
• MW: 214.2
• Purity: >98%
• Formula: C₁₁H₁₀N₄O
• SMILES: Nc1ccccc1NC(=O)c1cnccn1
• Target: Protein deacetylase
• Solubility: Soluble in DMSO (45 mg/ml)

Bioactivity

• Target IC50:
  HDAC2:2.2 μM|HDAC1:2 μM|HDAC3:289 nM|HDAC6:>20 μM
• In Vivo:
  In mice bearing MM.1S xenograft of human MM, BG45 (50 mg/kg, i.p.) significantly inhibits MM tumor growth. When in combination with bortezomib, BG45 (50 mg/kg, i.p.) enhances bortezomib-induced cytotoxicity.
• In Vitro:
  BG45 causes significant cell growth inhibition and induces caspase-dependent apoptosis in a series of MM cells. In RPMI8226 cells, BG45 synergistically enhances bortezomib-induced cytotoxicity.
• Cell Research:
  The growth inhibitory effects of BG45 in MM cell lines are assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) dye absorbance. To measure proliferation of MM cells, the rate of DNA synthesis is measured by [3H]thymidine uptake.(Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Histone deacetylases, HDAC, HDAC1, HDAC2, HDAC3, HDAC6, inhibit, Inhibitor, BG 45, BG45, BG-45, Apoptosis

Compound Identifiers

PubChem CID

16773791